49 results about "Total blood" patented technology

The present invention relates to a method of preparing analyses of total blood samples and to a device that is useful for implementing the method, said samples being conserved in tubes including at least one identification means for identifying the sample, the device comprising:

• • at least one compartment constituting a said storage zone for storing said tubes before and after analysis; and
  • at least one said read means for reading said identification means of said tubes; and
  • at least one preparation zone for preparing said blood samples prior to analysis and including means for verifying and/or treating said tubes containing said samples, and in particular at least one agitator means for agitating said tubes; and
  • at least one access zone giving access to at least one automatic analyzer of total blood, said access zone enabling a said tube to be placed in said analyzer; and
  • robotic gripper and displacement means controlled by an automatic controller and suitable for taking hold of and replacing said tubes individually in said storage zone and for conveying them in at least three directions XYZ between said storage zone, said preparation zone and said access zone giving access to said analyzer, said analyzer preferably being connected to and/or controlled by said automatic controller.

An oxygen concentration measurement system for blood hemoglobin comprises a multiple-wavelength low-coherence optical light source that is coupled by single mode fibers through a splitter and combiner and focused on both a target tissue sample and a reference mirror. Reflections from both the reference mirror and from the depths of the target tissue sample are carried back and mixed to produce interference fringes in the splitter and combiner. The reference mirror is set such that the distance traversed in the reference path is the same as the distance traversed into and back from the target tissue sample at some depth in the sample that will provide light attenuation information that is dependent on the oxygen in blood hemoglobin in the target tissue sample. Two wavelengths of light are used to obtain concentrations. The method can be used to measure total hemoglobin concentration [Hb.sub.deoxy +Hb.sub.oxy ] or total blood volume in tissue and in conjunction with oxygen saturation measurements from pulse oximetry can be used to absolutely quantify oxyhemoglobin [HbO.sub.2 ] in tissue. The apparatus and method provide a general means for absolute quantitation of an absorber dispersed in a highly scattering medium.

The invention relates to a separation disc on a multi-cell component mixed liquid separating system. The separation disc comprises a durable hard base disc and a disposable soft bag, wherein, a round disc composed of an inner core and a base seat is arranged on the hard base disc, a continuous cavity gap circling the axle of the centre of circle of the hard base disc and having a head part and a tail part which are not sealed is formed between the inner core and the base seat, the space between the outer side wall of the cavity gap and the outer side wall of the hard base disc is transparent, the soft bag adopts a single cavity structure equipped with an inlet pipe and an outlet pipe, and the soft bag can be arranged into the cavity gap; the application method comprises the following steps: the separation disc is positioned in the separating system to form a lamella of a single component through each component in the centrifuged and mixed liquid and according to the difference of the density, and then the lamella is accumulated to be thicker to extract the target component. The separation of the multi-cell component mixed liquid, for example, whole blood, by utilizing the separating system having the separation disc of the invention has the advantages of low cost, high preparation purity and high separating efficiency.

Systems, methods, and related computer program products for non-invasive NIR spectrophotometric (NIRS) monitoring of total blood hemoglobin levels and/or other blood constituent levels based on a hybrid combination of phase modulation spectrophotometry (PMS) and continuous wave spectrophotometry (CWS) are described. PMS-based measurements including both amplitude and phase information used in the determination of a non-pulsatile component of an absorption property for each of at least three distinct wavelengths are processed to compute PMS-derived intermediate information at least partially representative of a scattering characteristic. CWS-based measurements including amplitude information is processed in conjunction with the PMS-derived intermediate information to compute a pulsatile component of the absorption property. A metric representative of at least one chromophore level, such as the total blood hemoglobin level, is computed from the pulsatile component of the absorption property at the at least three wavelengths and displayed on an output display.

The invention provides a linear array SAR (Synthetic Aperture Radar) three-dimensional imaging method based on a threshold gradient tracking algorithm. The method comprises the steps of establishing a linear measurement model between linear array SAR original echo signals and a three-dimensional observation scene target scattering coefficient using a correlation among linear array SAR system parameters, motion platform parameters, space parameters of an observation scene target and original echo signals, and then reconstructing the observation scene target scattering coefficient using a TBGP (Total Blood Granulocyte Pool) method based on the signal linear measurement model. By using the contrast of maximum and minimum target scattering coefficients and the change rate of the target scattering coefficient as algorithm iteration termination conditions, the linear array SAR sparse imaging performance of a GP (Genetic Programming) algorithm under the condition that the sparsity of the observation scene is unknown is improved, the operation efficiency and the space storage efficiency are improved relative to an OMP (Orthogonal Matching Pursuit) algorithm, and the method can be applied in the fields of synthetic aperture radar imaging, earth remote sensing and the like.

Artificial dermis (1) obtained from plasma with platelets (2) and human fibroblasts. The plasma with platelets (2) is obtained from the fractionating of total blood (4) from the patient (8) by light centrifugation, and the human fibroblasts (3) from a skin biopsy (5). Clotting is obtained by adding calcium. This artificial dermis (1) provides for the rapid growth of the keratinocytes (6) seeded on its surface to build an artificial skin (7) which can easily be transplanted. Large areas of artificial dermis (1) are obtained from a small skin biopsy (5) and minimal quantities of plasma with platelets (2), which being enriched with cytokines and platelet growth factors, strengthens the proliferation of the cells seeded, both inside and on the surface. The artificial skin (7) obtained can be used to treat major burn treatments, chronic skin ulcers, etc., or be used, by employing genetically altered cells, as a vehicle for gene therapy.

Transducer modules for use in a blood analysis instrument and methods for analyzing a blood sample. The transducer modules presented generally include a light source, a focus-alignment system, a flow cell, and a light scatter detection system. Electrodes within the flow cell allow for the measurement of the DC impedance and RF conductivity of cells passing through a cell-interrogation zone in the flow cell. Light scatter from the cells passing through the cell-interrogation zone is measured by the light scatter detection system. The light scatter detection system measures the light scatter parameters of upper median light scatter, lower median angle light scatter, low angle light scatter, and axial light loss. The presented methods for analyzing a blood sample generally include aspirating a whole blood sample into a blood analysis instrument, preparing the blood sample for analysis, passing the blood sample through a flow cell in a transducer system, and measuring axial light loss, multiple angles of light scatter, DC impedance and/or RF conductivity.

Low molecular weight modified alginate and/or low molecular weight modified pectin, particularly modified citrus pectin (MCP), is useful in a composition for the treatment of diabetes, when administered to a diabetic individual. For instance, a composition comprising MCP is administered to an individual in an amount sufficient to reduce a parameter associated with diabetes severity, particularly levels of total blood glucose or triglyceride. The composition also may comprise well known pharmacologically acceptable agents, such as sulfured amino acids, cilantro, garlic, minerals, and herbs.

The invention relates to an antrodia camphorate composition. The composition is prepared from the following components in parts by weight: 100-135 parts of antrodia camphorate mycelia, 12-18 parts of coenzyme Q10, 15-30 parts of gynostemma pentaphylla, 20-35 parts of pseudo-ginseng, 5-12 parts of American ginseng, 3-6 parts of wolfberry fruits and 20-40 parts of olive extract. The antrodia camphorate composition can be used for lowering the contents of total blood serum cholesterol, low-density lipoprotein cholesterol and triglyceride and improving the content of high-density lipoprotein cholesterol; the liver damage can be reduced and the liver function can be improved; and the antrodia camphorate composition has the effects of activating blood and removing blood stasis, lowering blood pressure and preventing cardiovascular and cerebrovascular events, and also has the effects of lowering blood glucose, improving the immunity and resisting tumors.

The invention discloses a flow cytometry detection method of nitric oxide level of shrimp blood corpuscles. The flow cytometry detection method comprises the following steps of preparing shrimp blood corpuscle suspension liquid, co-culturing fluorochromes DAF-FM DA and shrimps blood corpuscles, and measuring DAF-FM average flourescence intensity of shrimp total blood corpuscles or blood corpuscles of different types through flow cytometry. The flow cytometry detection method is free from cell washing, avoids operation damage on the blood corpuscles, is high in accuracy, good in repeatability, large in measured quantity, simple, convenient and rapid to operate, and capable of analyzing cell nitric oxide level of different types at the same time, and provides a method basis for measuring the nitric oxide level of the shrimp blood corpuscles.

The invention discloses a method for detecting blood. The method comprises the following steps: controlling a sampling needle to collect an initial blood sample; controlling the sampling needle to distribute the initial blood sample to a blood routine examination module; controlling the sampling needle to collect a secondary blood sample in the blood routine examination module; controlling the sampling needle to distribute the secondary blood sample to a CRP measuring module; performing blood routine examination on the initial blood sample in the blood routine examination module; performing CRP detection on the secondary blood sample in the CRP measuring module. In a detection process, the secondary blood sample required by the CRP detection is collected by the initial blood sample in the blood routine examination module; the detection item is increased but the blood volume is not increased; the dosage of the collected initial blood sample is the total blood volume; no separating section sample is arranged; the total consumption of the blood sample is reduced and the waste is avoided. The invention also discloses a blood detecting device adopting the method for detecting blood.

The invention relates to an infant nourishment comprising lipid globules with a coating of phospholipids comprising dietary cholesterol. The infant nourishment has programming effects on the body and results in a reduced level of total blood cholesterol later in life when consuming a western style diet, and therefore the risk on western life style diseases as atherosclerosis and other vascular diseases later in life can be reduced.

The invention relates to a traditional Chinese medicine acupuncture and moxibustion needle for treating diseases in a medical department, a surgical department, a dermatological department, a gynecological department and a pain department. Patients feel afraid when seeing a traditional fire needle and refuse therapy, or the rate of fainting during acupuncture treatment is increased. A positioning electric fire needle overcomes the shortcomings. The entry depth of the traditional fire needle is totally based on experiences and feeling of a doctor, and accurate positioning cannot be realized. The traditional fire needle is heated by fire, but the positioning electric fire needle is heated by electricity and is convenient and fast in heating and is safe and sanitary. The positioning electric fire needle has effects of warming yang, removing coldness, dehumidifying, warming channels, dredging collaterals, promoting blood circulation, removing blood stasis, leading hotness to be discharged outwards, dispersing swelling, removing pus, ascending up spleen-qi, removing numbness and stopping itch. Modern medicine show that a warming effect of the fire needle can improve local or total blood circulation of a human body, metabolism of the human body is promoted, sterile inflammation is eliminated, and decompression is realized. Clinical application of the traditional Chinese medicine acupuncture and moxibustion needle does not need to be discriminated, and the needle can be used for treat diseases in aspects of wind, coldness, fire and poison.

The present invention provides the use of all-trans retinoic acid for the production of a pharmaceutical composition for the treatment of acute myeloid leukemia, which use is characterized in that the patients are selected from the group of non-M3 acute myeloid leukemia patients according to a physiologic concentration, e.g. a level of MN1 below a certain critical level analysed in total blood cells, preferably analysed in bone marrow cells. The critical level of MN1 can be determined according to known methods, e.g. by specific determination of the presence of MN1, e.g. using specific anti-MN1 antibody, e.g. in an ELISA or in another immuno specific assay. Preferably, the level of MN1 is determined at its transcription level, e.g. as the concentration of mRNA encoding MN1.

The present invention relates to methods, devices, instruments, processes, and systems for the highly specific, targeted molecular analysis of regions of human genomes and transcriptomes from the blood, i.e. from cell free circulating DNA, exosomes, microRNA, IncRNA, circulating tumor cells, or total blood cells. The technology enables highly sensitive identification and enumeration of mutation, expression, copy number, translocation, alternative splicing, and methylation changes using spatial multiplexing and combined nuclease, ligation, polymerase, and sequencing reactions. Such technology may be used for non-invasive early detection of cancer, non-invasive cancer prognosis, and monitoring both treatment efficacy and disease recurrence of cancer.

A system for monitoring blood flow in a patient comprises a first unit having an ultrasound transducer and a fastener for fastening the unit to the patient. A controller subsystem comprises the first unit and a separate second unit. The controller subsystem is configured to: control the ultrasound transducer to transmit plane-wave pulses into the patient in a propagation direction; sample reflections of the plane-wave pulses, received at the ultrasound transducer, from a region within the patient, to generate pulse-Doppler response signals; and process the pulse-Doppler response signals to estimate a series of values, over time, of a measure proportional, but not equal, to the total blood volume flow passing through the region. A monitoring subsystem is configured to monitor the series of values over time and to generate a signal if a set of one or more of the values satisfies a predetermined criterion.

The invention discloses an improved high-efficiency human autologous (Regulatory T cell) separation and amplification method. The improved high-efficiency human autologous separation and amplificationmethod comprises the following steps: S1, treating 5000mL of PB (Peripheral Blood) through a blood cell separator (single sampling machine) in 1 to 2 cycles, obtaining PBMCs (Peripheral Blood Mononuclear Cells) in order magnitude of 10*9 to 10*10, sieving separated PBMCs through a nylon net of which the pore diameter is 30 mum, and removing a cell cluster in suspension cells; S2, labeling non-CD4+ cells; S3, removing the non-CD4+ cells through negative selection of an LD separation column; S4, labeling cd25+ cells on an antibody; S5, positively selecting the CD25+ cells through an MS column.According to the improved high-efficiency human autologous separation and amplification method disclosed by the invention, 5000mL of peripheral blood can be treated through the blood cell separator (single acquisition machine) in 1 to 2 cycles, the PBMCs (Peripheral Blood Mononuclear Cells) in order magnitude of 10*9 to 10*10 can be obtained, and mononuclear cells of which the number is 100 timesor above of the number of the mononuclear cells obtained through a traditional blood sampling method can be easily obtained; other blood components are in direct feedback, so that waste is avoided, and the influence on total blood component and blood cell count of a patient is more slight.

Disclosed is a therapeutic management method of hypercholesterolemia in mammals. More specifically, the present invention relates to a method of reducing high levels of circulating cholesterol (hypercholesterolemia) in the blood stream of mammals, said method involving step of administering therapeutically effective amounts of Calebin A to said mammals to bring about the effects of (i) reducing the amount of total blood cholesterol levels; (ii) reducing the concentrations of low density lipoproteins (LDL) and very low density lipoproteins (VLDL); (iii) increasing the concentrations of high density lipoproteins (HDL) and (iv) reducing concentrations of serum triglycerides.

There is a continuing need for increased throughput in the examination of new chemical entities (NCEs) in terms of the pharmacokinetic (PK) parameters. The aim was to validate a new study method which allows a higher throughput, the examination of inter-animal variability and a reduction in the numbers of animals needed for routine bioavailability studies of NCEs in awake rats. The design uses a new method for intravenous (iv) administration via the saphenous vein in combination with serial blood sampling via the tail vein. The multiple sampling method was compared with single sampling (decapitation) and the effect on haematocrit (Hct) levels was studied. Direct injection in the saphenous vein was compared to iv administration using an indwelling jugular catheter. Using structural different CE's, it was shown that a combination of direct injection via the saphenous vein and multiple sampling from the tail vein produces comparable plasma concentrations and subsequent PK results to the comparator methods. Furthermore, Hct levels remained within recommended levels using a total blood sampling volume of up to 2.1 ml per day. The new technique increases throughput by reducing the time required for preparative surgery, increases the quality by allowing inter-animal comparison of major PK parameters as concentration time curves can be collected from each animal and reduces the number of animals required.

The invention provides a PRP preparing device and a PRP preparing method, and relates to the technical field of PRP preparation. The problems that the PRP preparation time is long, the contamination risk is high and the total blood drawing volume of a patient is high in the prior art are solved. The PRP preparing device comprises a sterile protection cover and a filtration membrane arranged in thesterile protection cover. The sterile protection cover is provided with a blood sampling tube connecting port and a centrifugal tube connecting port. The circumference of the filtration membrane is connected with the inner wall of the sterile protection cover. The filtration membrane is located between the blood sampling tube connecting port and the centrifugal tube connecting port. The filtration membrane comprises at least one single-layer polyester fiber non-woven fabric without charges. The filtration aperture of the filtration membrane is smaller than or equal to 7 [mu]m. In the method,PRP is prepared through a sampling tube, a centrifugal tube, a centrifugal machine and the PRP preparing device, high-concentration PRP can be more rapidly obtained, the contamination risk is reduced,the preparation time is shortened, the total blood drawing volume of the patient is reduced, blood waste is reduced, and the purpose that red blood cells are prevented from covering a filtration membrane when being filtered out is realized.